Johannes Nowak1, Carolin Seidel1, Torsten Pietsch1, Balint Alkonyi1, Taylor Laura Fuss1, Carsten Friedrich1, Katja von Hoff1, Stefan Rutkowski1, Monika Warmuth-Metz1. 1. Reference Center for Neuroradiology, University Hospital of Würzburg, Würzburg, Germany (J.N., C.S., B.A., M.W.-M.); Department of Radiology, University Hospital of Würzburg, Würzburg, Germany (J.N.); Department of Radiology, Pathology Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts (C.S., T.L.F.); Department of Neuropathology, Brain Tumor Reference Center, Bonn, Germany (T.P.); Department of Pediatric Hematology and Oncology, University Medical Center Hamburg- Eppendorf, Hamburg, Germany (C.F., K.v.H., S.R.); Division of Pediatric Oncology, Hematology and Hemostaseology, Department of Women's and Children's Health, University Hospital Leipzig, Leipzig, Germany (C.F.).
Abstract
BACKGROUND: Ependymoblastoma (EBL), ependymoma (EP), and primitive neuroectodermal tumors of the central nervous system not otherwise specified (CNS-PNET NOS) are pediatric brain tumors that can be differentiated by histopathology in the clinical setting. Recently, we described specific MRI features of EBL. In this study, we compare standardized MRI characteristics of EBL with EP and CNS-PNET NOS in a series comprising 22 patients in each group. METHODS: All 66 centrally reviewed cases were obtained from the database of the German multicenter HIT trials. We systematically analyzed the initial MRI scans at diagnosis according to standardized criteria, and paired comparison was performed for EBL and EP, as well as for EBL and CNS-PNET NOS. RESULTS: We found differences between EBL and EP regarding age at diagnosis, MR signal intensity, tumor margin and surrounding edema, presence and size of cysts, and contrast enhancement pattern. Although MRI appearance of EBL shares many features with CNS-PNET NOS, we revealed significant differences in terms of age at diagnosis, tumor volume and localization, tumor margins, edema, and contrast enhancement. CONCLUSION: This is the first study that systematically compares multiple parameters of MRI in pediatric EBL with findings in EP and CNS-PNET NOS. Although a definite differentiation by means of MRI alone might not be feasible in the individual case, we identify significant differences between these tumor entities.
BACKGROUND:Ependymoblastoma (EBL), ependymoma (EP), and primitive neuroectodermal tumors of the central nervous system not otherwise specified (CNS-PNET NOS) are pediatric brain tumors that can be differentiated by histopathology in the clinical setting. Recently, we described specific MRI features of EBL. In this study, we compare standardized MRI characteristics of EBL with EP and CNS-PNET NOS in a series comprising 22 patients in each group. METHODS: All 66 centrally reviewed cases were obtained from the database of the German multicenter HIT trials. We systematically analyzed the initial MRI scans at diagnosis according to standardized criteria, and paired comparison was performed for EBL and EP, as well as for EBL and CNS-PNET NOS. RESULTS: We found differences between EBL and EP regarding age at diagnosis, MR signal intensity, tumor margin and surrounding edema, presence and size of cysts, and contrast enhancement pattern. Although MRI appearance of EBL shares many features with CNS-PNET NOS, we revealed significant differences in terms of age at diagnosis, tumor volume and localization, tumor margins, edema, and contrast enhancement. CONCLUSION: This is the first study that systematically compares multiple parameters of MRI in pediatric EBL with findings in EP and CNS-PNET NOS. Although a definite differentiation by means of MRI alone might not be feasible in the individual case, we identify significant differences between these tumor entities.
Authors: W G Armington; A G Osborn; D A Cubberley; H R Harnsberger; R Boyer; T P Naidich; R G Sherry Journal: Radiology Date: 1985-11 Impact factor: 11.105
Authors: Marco Gessi; André O von Bueren; Andras Treszl; Anja zur Mühlen; Wolfgang Hartmann; Monika Warmuth-Metz; Stefan Rutkowski; Torsten Pietsch Journal: Neuro Oncol Date: 2014-07 Impact factor: 12.300
Authors: J Nowak; C Seidel; F Berg; T Pietsch; C Friedrich; K von Hoff; S Rutkowski; M Warmuth-Metz Journal: AJNR Am J Neuroradiol Date: 2014-06-19 Impact factor: 3.825
Authors: V Dangouloff-Ros; A Tauziède-Espariat; C-J Roux; R Levy; D Grévent; F Brunelle; A Gareton; S Puget; K Beccaria; T Blauwblomme; J Grill; C Dufour; P Varlet; N Boddaert Journal: AJNR Am J Neuroradiol Date: 2019-03-07 Impact factor: 3.825
Authors: A Jaju; E I Hwang; M Kool; D Capper; L Chavez; S Brabetz; C Billups; Y Li; M Fouladi; R J Packer; S M Pfister; J M Olson; L A Heier Journal: AJNR Am J Neuroradiol Date: 2019-10-10 Impact factor: 3.825
Authors: M Zhang; L Tam; J Wright; M Mohammadzadeh; M Han; E Chen; M Wagner; J Nemalka; H Lai; A Eghbal; C Y Ho; R M Lober; S H Cheshier; N A Vitanza; G A Grant; L M Prolo; K W Yeom; A Jaju Journal: AJNR Am J Neuroradiol Date: 2022-03-31 Impact factor: 3.825
Authors: Julia E Neumann; Annika K Wefers; Sander Lambo; Edoardo Bianchi; Marie Bockstaller; Mario M Dorostkar; Valerie Meister; Pia Schindler; Andrey Korshunov; Katja von Hoff; Johannes Nowak; Monika Warmuth-Metz; Marlon R Schneider; Ingrid Renner-Müller; Daniel J Merk; Mehdi Shakarami; Tanvi Sharma; Lukas Chavez; Rainer Glass; Jennifer A Chan; M Mark Taketo; Philipp Neumann; Marcel Kool; Ulrich Schüller Journal: Nat Med Date: 2017-09-11 Impact factor: 53.440
Authors: Roberta Rudà; Guido Reifenberger; Didier Frappaz; Stefan M Pfister; Anne Laprie; Thomas Santarius; Patrick Roth; Joerg Christian Tonn; Riccardo Soffietti; Michael Weller; Elizabeth Cohen-Jonathan Moyal Journal: Neuro Oncol Date: 2018-03-27 Impact factor: 12.300